Viral infectivity in as little as a day.

Diagram showing how AVIA's use of machine learning and brightfield imaging dramatically reduces viral infectivity.

ViQi’s Automated Viral Infectivity Assay (AVIA™) is an AI-based assay that uses machine learning and brightfield microscopy to detect phenotypic changes associated with viral infection prior to human visibility

  • Plaque Assays

  • TCID-50s

  • Fluorescent Labeling

Replaces

  • Titration

  • Inactivation

  • Neutralization

  • Viral Clearance

Applies to

AVIA Advantage

ViQi customers are first interested in AVIA for its increased capacity and are further impressed by its superior precision and numerous additional benefits:

Viral infectivity confirmation in under 2 days

Precision of ± 20%

10x+ increase throughput with automation

More cost-effective and sustainable

No staining required

Significant advantages with BSL3/BSL4 viruses

Requires less training and no prior experience

Elegant Solutions for Complex Challenges

ViQi has successfully trained AIs for more than 15 forward-thinking labs at large pharmaceutical companies, CRO/CDMOs, biotechs, and academic institutions. These labs are focused on a broad range of viral infectivity assay applications in R&D, bioprocessing, cell/gene therapy, oncolytic viral immunotherapy, viral clearance, and manufacturing.

Our flexible solution has demonstrated effectiveness against a diverse array of viruses, encompassing both RNA and DNA viruses, as well as enveloped and non-enveloped types. With a proven track record of success against over 15 different viruses, multiple cell lines, and various imaging devices, we are confident in our ability to provide a reliable and effective solution tailored to your specific requirements.

We understand the importance of developing a rigorous assay that can meet regulatory demands, including GMP-readiness. We work closely with our customers to ensure proper validation of the assay according to ICH guidelines and other regulatory requirements, such as GxP compliance. Our FDA Class 1 MDDS platform provides the necessary peace of mind to know that your data and results are securely managed at ViQi.

Scientists confirming compliance and regulatory demands.

Let us Guide You in Unlocking the Power of AI in Your Research.


Some of our AVIA Partners

Working Together is Easy

The ViQI  team understands the importance of a streamlined and validated assay setup process. We collaborate with you to develop a tailored experimental protocol for your specific virus and cell line, considering the unique requirements of your laboratory. We will assist in the proper configuration of your automated imager and work closely with your IT team to ensure secure data uploads to our Amazon Web Services account.

Your Role

ViQi’s Role

Provide a customized experimental protocol.

Provide your own cells, viruses and automated imager.


Transfer your image files and experimental metadata to ViQi’s platform using our convenient drag-and-drop feature.

Access ViQi’s Software-as-a-Service (SaaS) platform through a standard web browser to view the provenance of all analysis results and stored images

Interested in a demo?
Learn how AI accelerates your drug development workflows.

Train and validate a customized AI model.


Deliver analytical reports within one hour using trained AI models

Provide imaging and IT support to meet technical requirements and ensure a seamless workflow.

Image 96-well plates in brightfield. Imaging time is 5-40 minutes per plate depending on  the imager model.


Let’s discuss your goals and objectives for your virus and cell line.